1. Home
  2. SCLXW vs OXLCN Comparison

SCLXW vs OXLCN Comparison

Compare SCLXW & OXLCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLXW
  • OXLCN
  • Stock Information
  • Founded
  • SCLXW N/A
  • OXLCN N/A
  • Country
  • SCLXW United States
  • OXLCN United States
  • Employees
  • SCLXW 111
  • OXLCN N/A
  • Industry
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • OXLCN Investment Managers
  • Sector
  • SCLXW Health Care
  • OXLCN Finance
  • Exchange
  • SCLXW Nasdaq
  • OXLCN Nasdaq
  • Market Cap
  • SCLXW N/A
  • OXLCN N/A
  • IPO Year
  • SCLXW N/A
  • OXLCN N/A
  • Fundamental
  • Price
  • SCLXW $0.46
  • OXLCN $24.10
  • Analyst Decision
  • SCLXW
  • OXLCN
  • Analyst Count
  • SCLXW 0
  • OXLCN 0
  • Target Price
  • SCLXW N/A
  • OXLCN N/A
  • AVG Volume (30 Days)
  • SCLXW 4.0K
  • OXLCN N/A
  • Earning Date
  • SCLXW 03-07-2025
  • OXLCN N/A
  • Dividend Yield
  • SCLXW N/A
  • OXLCN N/A
  • EPS Growth
  • SCLXW N/A
  • OXLCN N/A
  • EPS
  • SCLXW N/A
  • OXLCN N/A
  • Revenue
  • SCLXW $55,152,000.00
  • OXLCN N/A
  • Revenue This Year
  • SCLXW N/A
  • OXLCN N/A
  • Revenue Next Year
  • SCLXW N/A
  • OXLCN N/A
  • P/E Ratio
  • SCLXW N/A
  • OXLCN N/A
  • Revenue Growth
  • SCLXW 22.02
  • OXLCN N/A
  • 52 Week Low
  • SCLXW $0.18
  • OXLCN N/A
  • 52 Week High
  • SCLXW $0.18
  • OXLCN N/A
  • Technical
  • Relative Strength Index (RSI)
  • SCLXW N/A
  • OXLCN 43.22
  • Support Level
  • SCLXW N/A
  • OXLCN $24.08
  • Resistance Level
  • SCLXW N/A
  • OXLCN $24.37
  • Average True Range (ATR)
  • SCLXW 0.00
  • OXLCN 0.08
  • MACD
  • SCLXW 0.00
  • OXLCN -0.01
  • Stochastic Oscillator
  • SCLXW 0.00
  • OXLCN 6.56

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About OXLCN Oxford Lane Capital Corp.

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

Share on Social Networks: